Loading...
•
Mar 31, 2020
Baxter Q1 2020 Earnings Report
Baxter's Q1 2020 results were reported, showing revenue growth and increased demand for specific products due to the COVID-19 pandemic.
Key Takeaways
Baxter's Q1 2020 revenue reached $2.8 billion, a 6% increase, with adjusted EPS of $0.82, up 9%. The company benefited from increased demand for essential medical products during the COVID-19 pandemic and is expanding production to meet global needs.
First-quarter revenue of $2.8 billion increased 6% on a reported basis.
U.S. GAAP earnings per share (EPS) of $0.64 declined 3 percent; Adjusted EPS of $0.82 increased 9 percent.
Baxter is taking rapid action on multiple fronts in response to the COVID-19 pandemic, including boosting capacity and production.
The company received U.S. FDA emergency use authorization (EUA) for the Oxiris filter set.
Baxter
Baxter
Baxter Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Given the high-degree of uncertainty around the potential financial impacts from the COVID-19 pandemic on Baxter’s operations, the company is not in a position to provide guidance for the second quarter or full-year 2020 at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income